In summary, we have shown that BCL2 is an independent prognostic marker in two large series of breast cancer [21] and, here, provide an estimate of the average size of this association with outcome in a meta-analysis on 16 other series totalling over 5,000 patients. Here, BCL2 is linked to breast carcinoma.